AstraZeneca

(AZN)
Sector: Pharmaceuticals & Biotechnology
10,802.00p
-104.00p -0.95
Last updated: 17:15:00

Company News Headlines

Date Time Headline Source
24/07/2025 07:00 Gefurulimab nanobody met Phase III endpoints RNS
22/07/2025 07:00 AstraZeneca plans to invest $50bn in the US RNS
16/07/2025 07:00 Update on anselamimab in AL amyloidosis RNS
14/07/2025 07:00 Baxdrostat met primary endpt in BaxHTN PhIII trial RNS
04/07/2025 07:00 Imfinzi approved in the EU for bladder cancer RNS
01/07/2025 15:00 Total Voting Rights RNS
24/06/2025 07:00 Datroway approved in US for EGFRm lung cancer RNS
17/06/2025 11:45 Holding(s) in Company RNS
13/06/2025 09:30 AstraZeneca enters into collaboration with CSPC RNS
12/06/2025 15:00 Director/PDMR Shareholding RNS
06/06/2025 07:00 Fixed-duration Calquence approved in EU for 1L CLL RNS
02/06/2025 15:05 Block listing Interim Review RNS
02/06/2025 15:00 Total Voting Rights RNS
27/05/2025 07:00 Imfinzi recommended in EU for bladder cancer RNS
23/05/2025 10:00 Director/PDMR Shareholding RNS
21/05/2025 13:45 Director Declaration RNS
20/05/2025 07:00 Acquisition of EsoBiotec completed RNS
09/05/2025 07:00 Imfinzi improved DFS in early bladder cancer RNS
07/05/2025 07:30 Enhertu improved pCR in early-stage breast cancer RNS
06/05/2025 07:00 Calquence combination approved in EU for 1L MCL RNS
02/05/2025 07:00 Breztri met primary endpoints in Ph3 asthma trials RNS
01/05/2025 16:00 Director/PDMR Shareholding RNS
01/05/2025 15:00 Total Voting Rights RNS
29/04/2025 07:10 Fixed-duration Calquence recommended in EU for CLL RNS
29/04/2025 07:05 Update on CAPItello-280 Phase III trial RNS
29/04/2025 07:00 1st Quarter Results RNS
22/04/2025 07:00 Enhertu combination improved PFS in 1L HER2+ mBC RNS
11/04/2025 17:30 Result of AGM RNS
04/04/2025 07:05 Imfinzi approved in EU for AEGEAN RNS
04/04/2025 07:00 Enhertu approved in EU in post-ET breast cancer RNS
01/04/2025 15:00 Total Voting Rights RNS
31/03/2025 07:05 Calquence recommended for EU approval in 1L MCL RNS
31/03/2025 07:00 Imfinzi approved in the US for bladder cancer RNS
21/03/2025 10:58 AZN invests $2.5bn in Beijing R&D & manufacturing RNS
17/03/2025 07:10 Eneboparatide Phase III trial met primary endpoint RNS
17/03/2025 07:05 Imfinzi approved in EU for limited-stage SCLC RNS
17/03/2025 07:00 AstraZeneca to acquire EsoBiotec RNS
12/03/2025 18:00 Holding(s) in Company RNS
07/03/2025 15:00 Director/PDMR Shareholding RNS
07/03/2025 11:00 Notice of AGM RNS
07/03/2025 07:00 Imfinzi improved EFS in early-stage gastric cancer RNS
06/03/2025 15:00 Director/PDMR Shareholding RNS
05/03/2025 15:00 Director/PDMR Shareholding RNS
03/03/2025 15:00 Total Voting Rights RNS
03/03/2025 07:00 Imfinzi recommended for EU approval for AEGEAN RNS
28/02/2025 13:00 Enhertu recommended in EU in post-ET breast cancer RNS
26/02/2025 07:00 Camizestrant improved PFS in 1L HR+ breast cancer RNS
19/02/2025 07:00 Filing of Form 20-F with SEC RNS
18/02/2025 14:00 Holding(s) in Company RNS
18/02/2025 11:00 Annual Financial Report RNS